Additionally, a study by Wahba et al. reported that treatment with a PD-1 inhibitor in combination with paclitaxel and chimeric antigen receptor (CAR) T cells targeting ErbB homo-and hetero-dimer (T4 immunotherapy) promoted a synergistic reduction in tumor burden, compared to either treatment alone [60]. The gene discussed is PDCD1; the disease is neoplasm.